EFFICACY OF COMBINED ADMINISTRATION OF RIDOSTIN AND OSELTAMIVIR (TAMIFLU) FOR THERAPY AND PROPHYLAXIS OF EXPERIMENTAL INFECTION INDUCED BY INFLUENZA VIRUS A (H5N1) IN MICE


Cite item

Full Text

Abstract

Aim. Study of possibility of treatment-prophylaxis effect increase during combined administration of ridostin and tamiflu in experiments in mice infected with highly pathogenic influenza virus strain A/chicken/Kurgan/05/2005 (H5N1). Materials and methods. Balb/c line mice infected intranasally with influenza virus at 100 and 10 LD 50 doses received ridostin and tamiflu as monopreparation or the combined variant before or after the infection. The mice were observed for 16 days, lethality rate, protection coefficient and average life span were evaluated. Virus concentration in lungs was determined by using titration in MDCK cell line. Results. Combined administration of ridostin and tamiflu after the infection increased survivability of the animals when compared with the control group, and reduced influenza virus concentration in lungs. Conclusion. Treatment effect during combined administration of ridostin and tamiflu after influenza virus infection increased.

About the authors

M. O Skarnovich

State Scientific Center of Virology and Biotechnology «Vector», Koltsovo, Novosibirsk Region, Russia

L. N Shishkina

State Scientific Center of Virology and Biotechnology «Vector», Koltsovo, Novosibirsk Region, Russia

A. S Kabanov

State Scientific Center of Virology and Biotechnology «Vector», Koltsovo, Novosibirsk Region, Russia

N. A Mazurkova

State Scientific Center of Virology and Biotechnology «Vector», Koltsovo, Novosibirsk Region, Russia

E. D Danilenko

State Scientific Center of Virology and Biotechnology «Vector», Koltsovo, Novosibirsk Region, Russia

V. I Masycheva

State Scientific Center of Virology and Biotechnology «Vector», Koltsovo, Novosibirsk Region, Russia

I. G Drozdov

State Scientific Center of Virology and Biotechnology «Vector», Koltsovo, Novosibirsk Region, Russia

References

  1. Аликин Ю.С., Веревкина К.Н., Дубатолова Т.Д. и др. Индуктор интерферона Ридостин. Патент РФ № 2083221. БИ №19, 1997.
  2. Грипп: Руководство для врачей. Г.И. Карпухин (ред.). СПб., 2001.
  3. Ершов Ф.И., Романцев М.Г. Лекарственные средства, применяемые при вирусных заболеваниях. М., 2007.
  4. Реброва О. Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М., 2006.
  5. Руководство по содержанию и использованию лабораторных животных. Washington, D.C., National Akademy Press, 1996.
  6. Сухинин В. П., Зарубаев В. В. Платонов В. Г. Защитное действие циклоферона при экспериментальной гриппозной инфекции. Вопр. вирусол. 2000, 5: 26-31.
  7. Kamps B.S., Hoffmann C., Preiser W. Influenza Report 2006. www.InfluenzaReport.com.
  8. Li K.S., Guan Y., Wang J. et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature. 2004, 430 (6996): 209-213.
  9. Watts J. Asian nations step up action to curb spread of avian influenza. Lancet. 2004, 363 (9406): 373.
  10. WHO Rapid Advice Guidelines on pharmacological management of humans infected with

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Skarnovich M.O., Shishkina L.N., Kabanov A.S., Mazurkova N.A., Danilenko E.D., Masycheva V.I., Drozdov I.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies